Drugs / HH2710
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04198818 | Jan 2020 → Mar 2023 | Erdheim-Chester disease, melanoma, metastatic neoplasm, non-small cell lung carcinoma | Haihe Biopharma Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HH2710 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04198818 ↗ |
| Action | Inhibit | “HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range.” NCT04198818 ↗ |
| Modality | Small molecule | “HH2710 is a small molecule” NCT04198818 ↗ |